Altitude Life Science Ventures
Altitude Life Science Ventures is a venture capital firm that invests in early-stage life science companies. The firm focuses on markets with significant demand and growth potential, backing high-quality teams to build strong, defensible, and long-term businesses. Their investment scope includes therapeutics, diagnostics, gene editing, AI/machine learning therapeutics, medical devices, and more. Altitude leverages its expertise in intellectual property strategic planning to maximize and preserve the value of its portfolio companies.
Altitude Life Science Ventures
What We Do
Altitude provides IP strategic planning services, integrating fundamental activities of early-stage life science companies with the creation, development, and presentation of the company’s IP portfolio on a worldwide basis. This includes developing multiple levels of protection to complement the maturation of the company and development of the technology, confirm competitive advantages, preserve product opportunities, complement R&D activities, support business development, and maximize the value of the company’s technology.
Industry Focus
Show More (1)Portfolio
Harnessing the regulatory genome to create next-generation molecular therapies
#Genomics
Developing novel therapeutics using precision medicine approaches to neuroscience drug development
#Biotechnology
Bringing the combined power of high-technology engineering and advanced biosynthesis to RNA therapeutics
#Biotechnology
Developing defined complex microbial communities to provide a robust and lasting cure for high unmet need diseases
#Biotechnology
A cellular immunotherapy company creating a hybrid platform that integrates innate and adaptive programs to eliminate disease
#Biotechnology
Pioneering Gene Writing™—a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source
#Biotechnology
Developing a machine learning-powered platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics
#Biotechnology
Focused on cellular rejuvenation programming to restore cell health and resilience, with the goal of reversing disease to transform medicine
#Biotechnology
Developing a small molecule therapeutics platform for addressing strongly validated yet historically undruggable targets in oncology, rare diseases, neurodegeneration and autoimmunity
#Biotechnology
Proprietary delivery platform, based on endogenous human proteins, offers the potential to enable genetic medicines across a broad range of modalities and therapeutic areas
#Biotechnology
Developing CD8 T cell immune modulators for the treatment of autoimmune diseases
#Biotechnology
Developing microscale robots to deliver biologics or small molecule therapies locally to targeted disease
#Biotechnology
Computational biotechnology company creating a novel class of medicines to precisely target disease biology
#Biotechnology
Creating endless RNA (eRNA™) —a new class of programmable medicines capable of expressing therapeutic proteins inside the body.
#Biotechnology
Developing first-in-class gene therapies, Anellovector™ therapies, using a novel viral vector platform based on its groundbreaking work on the human commensal virome
#Biotechnology
Developing drugs that reprogram cellular microenvironments to send signals intended to have curative effects.
#Biotechnology